<DOC>
	<DOCNO>NCT00193271</DOCNO>
	<brief_summary>This trial evaluate feasibility , toxicity , efficacy docetaxel/estramustine , adjuvant therapy patient high-risk prostate cancer definitive local therapy .</brief_summary>
	<brief_title>Adjuvant Docetaxel Estramustine Phosphate High Risk Localized Prostate Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Docetaxel + Estramustine</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<criteria>To include study , must meet following criterion : Histologically confirm adenocarcinoma prostate Clinically surgically stag localized disease , stage IIII . Prior surgical resection radiation therapy curative intent No clinical evidence residual disease Gleason 's combine score &gt; 7 . Age &gt; 18 year . No prior chemotherapy prostate cancer . No previous androgen deprivation therapy prostate cancer Able perform activity daily live minimal assistance Adequate bone marrow , liver kidney function Voluntarily provide write informed consent . You participate study follow apply : History prior malignancy past five year History significant heart disease within previous 6 month Cerebral vascular accident ( CVA ) stroke within previous 6 month . Moderate severe peripheral neuropathy Previous therapy injectable radioisotope . Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>